BR0308904A - Método de tratamento de gastroparesia, e, uso de um composto de glp-1 - Google Patents
Método de tratamento de gastroparesia, e, uso de um composto de glp-1Info
- Publication number
- BR0308904A BR0308904A BR0308904-5A BR0308904A BR0308904A BR 0308904 A BR0308904 A BR 0308904A BR 0308904 A BR0308904 A BR 0308904A BR 0308904 A BR0308904 A BR 0308904A
- Authority
- BR
- Brazil
- Prior art keywords
- glp
- gastroparesis
- treatment
- compound
- compounds
- Prior art date
Links
- 206010021518 Impaired gastric emptying Diseases 0.000 title abstract 3
- 208000001288 gastroparesis Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 230000030136 gastric emptying Effects 0.000 abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- -1 GLP-1 COMPOUND Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
"MéTODO DE TRATAMENTO DE GASTROPARESIA, E, USO DE UM COMPOSTO DE GLP- 1". A invenção refere-se ao uso de compostos de GLP-1 para o tratamento de gastroparesia. Paciente com gastroparesia em geral experimenta um retardamento no esvaziamento gástrico. Compostos de GLP-1 podem ser utilizados para o esvaziamento gástrico nestes pacientes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37165002P | 2002-04-10 | 2002-04-10 | |
| PCT/US2003/008457 WO2003087139A2 (en) | 2002-04-10 | 2003-03-27 | Treatment of gastroparesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0308904A true BR0308904A (pt) | 2005-05-03 |
Family
ID=29250714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0308904-5A BR0308904A (pt) | 2002-04-10 | 2003-03-27 | Método de tratamento de gastroparesia, e, uso de um composto de glp-1 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20050164925A1 (pt) |
| EP (1) | EP1496924A4 (pt) |
| JP (1) | JP2005530732A (pt) |
| KR (1) | KR20040098063A (pt) |
| CN (1) | CN1735423A (pt) |
| AU (1) | AU2003220403A1 (pt) |
| BR (1) | BR0308904A (pt) |
| CA (1) | CA2480858A1 (pt) |
| EA (1) | EA200401345A1 (pt) |
| EC (1) | ECSP045345A (pt) |
| HR (1) | HRP20040939A2 (pt) |
| IL (1) | IL164266A0 (pt) |
| MX (1) | MXPA04009929A (pt) |
| NO (1) | NO20044815L (pt) |
| NZ (1) | NZ535684A (pt) |
| PL (1) | PL373658A1 (pt) |
| WO (1) | WO2003087139A2 (pt) |
| ZA (1) | ZA200408111B (pt) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
| US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| TW200526254A (en) * | 2003-09-19 | 2005-08-16 | Novo Nordisk As | Novel GLP-1 derivatives |
| JP2007537981A (ja) * | 2003-09-19 | 2007-12-27 | ノボ ノルディスク アクティーゼルスカブ | 新規の血漿タンパク質親和性タグ |
| US8612016B2 (en) | 2004-08-18 | 2013-12-17 | Metacure Limited | Monitoring, analysis, and regulation of eating habits |
| WO2006087712A2 (en) | 2005-02-17 | 2006-08-24 | Metacure N.V. | Charger with data transfer capabilities |
| US9821158B2 (en) | 2005-02-17 | 2017-11-21 | Metacure Limited | Non-immediate effects of therapy |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| RU2007134155A (ru) | 2005-03-18 | 2009-04-27 | Ново Нордиск А/С (DK) | Glp-1 соединения с увеличенным временем полужизни |
| WO2007080595A2 (en) | 2006-01-12 | 2007-07-19 | Metacure N.V. | Electrode assemblies, tools, and methods for gastric wall implantation |
| EP1861160B1 (en) * | 2005-03-24 | 2011-11-16 | Metacure Limited | Wireless leads for gastrointestinal tract applications |
| EP1890763A4 (en) | 2005-06-02 | 2017-05-03 | Metacure Limited | Gi lead implantation |
| US8442841B2 (en) * | 2005-10-20 | 2013-05-14 | Matacure N.V. | Patient selection method for assisting weight loss |
| US8295932B2 (en) | 2005-12-05 | 2012-10-23 | Metacure Limited | Ingestible capsule for appetite regulation |
| AU2012203915B9 (en) * | 2006-04-20 | 2014-10-09 | Amgen Inc. | GLP-1 compounds |
| EP2007804B1 (en) * | 2006-04-20 | 2014-06-18 | Amgen, Inc | Glp-1 compounds |
| EP2150308B1 (en) * | 2007-05-09 | 2018-08-08 | MetaCure Limited | Analysis and regulation of food intake |
| US8423130B2 (en) * | 2008-05-09 | 2013-04-16 | Metacure Limited | Optimization of thresholds for eating detection |
| KR20110039348A (ko) | 2008-08-06 | 2011-04-15 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질 |
| WO2010084173A1 (en) | 2009-01-22 | 2010-07-29 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
| CN102612376A (zh) | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内功效的生长激素 |
| WO2011017554A2 (en) * | 2009-08-07 | 2011-02-10 | Mannkind Corporation | Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome |
| MX345736B (es) | 2010-01-22 | 2017-02-14 | Novo Nordisk Healthcare Ag | Hormonas de crecimiento con eficacia in vivo prolongada. |
| CA2787895A1 (en) | 2010-01-22 | 2011-07-28 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
| US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
| WO2011136361A1 (ja) | 2010-04-30 | 2011-11-03 | 株式会社 三和化学研究所 | 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| CA2894765A1 (en) | 2012-12-21 | 2014-06-26 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| ES2841123T3 (es) | 2013-04-05 | 2021-07-07 | Formulacion Del Compuesto De La Hormona De Crecimiento | Formulación del compuesto de la hormona de crecimiento |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US5981488A (en) * | 1997-03-31 | 1999-11-09 | Eli Lillly And Company | Glucagon-like peptide-1 analogs |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
-
2003
- 2003-03-27 KR KR10-2004-7016025A patent/KR20040098063A/ko not_active Ceased
- 2003-03-27 EA EA200401345A patent/EA200401345A1/ru unknown
- 2003-03-27 EP EP03716707A patent/EP1496924A4/en not_active Withdrawn
- 2003-03-27 MX MXPA04009929A patent/MXPA04009929A/es not_active Application Discontinuation
- 2003-03-27 CA CA002480858A patent/CA2480858A1/en not_active Abandoned
- 2003-03-27 BR BR0308904-5A patent/BR0308904A/pt not_active IP Right Cessation
- 2003-03-27 NZ NZ535684A patent/NZ535684A/xx unknown
- 2003-03-27 JP JP2003584094A patent/JP2005530732A/ja active Pending
- 2003-03-27 HR HRP20040939 patent/HRP20040939A2/hr not_active Application Discontinuation
- 2003-03-27 US US10/508,762 patent/US20050164925A1/en not_active Abandoned
- 2003-03-27 AU AU2003220403A patent/AU2003220403A1/en not_active Abandoned
- 2003-03-27 IL IL16426603A patent/IL164266A0/xx unknown
- 2003-03-27 CN CNA038080079A patent/CN1735423A/zh active Pending
- 2003-03-27 PL PL03373658A patent/PL373658A1/xx unknown
- 2003-03-27 WO PCT/US2003/008457 patent/WO2003087139A2/en not_active Ceased
-
2004
- 2004-10-07 ZA ZA200408111A patent/ZA200408111B/xx unknown
- 2004-10-08 EC EC2004005345A patent/ECSP045345A/es unknown
- 2004-11-05 NO NO20044815A patent/NO20044815L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL373658A1 (en) | 2005-09-05 |
| MXPA04009929A (es) | 2006-03-10 |
| NO20044815L (no) | 2005-01-07 |
| WO2003087139A3 (en) | 2004-01-08 |
| CN1735423A (zh) | 2006-02-15 |
| US20050164925A1 (en) | 2005-07-28 |
| WO2003087139A2 (en) | 2003-10-23 |
| EA200401345A1 (ru) | 2005-08-25 |
| EP1496924A4 (en) | 2007-05-30 |
| KR20040098063A (ko) | 2004-11-18 |
| HRP20040939A2 (en) | 2004-12-31 |
| JP2005530732A (ja) | 2005-10-13 |
| EP1496924A2 (en) | 2005-01-19 |
| ECSP045345A (es) | 2006-04-19 |
| AU2003220403A1 (en) | 2003-10-27 |
| NZ535684A (en) | 2006-03-31 |
| ZA200408111B (en) | 2005-10-07 |
| CA2480858A1 (en) | 2003-10-23 |
| IL164266A0 (en) | 2005-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0308904A (pt) | Método de tratamento de gastroparesia, e, uso de um composto de glp-1 | |
| SG158731A1 (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
| MY145590A (en) | Phenylacetamides and their use as glucokinase modulators | |
| MXPA03003870A (es) | Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes. | |
| WO2003009838A1 (en) | Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus | |
| EA200300026A1 (ru) | Аналоги глюкагоноподобного пептида-1 | |
| GB0223038D0 (en) | Therapeutic compounds | |
| ATE320257T1 (de) | (s,s)-reboxetine zur behandlung chronischer schmerzen | |
| BR0212042A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto | |
| IL158593A0 (en) | Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders | |
| GB0225474D0 (en) | Therapeutic agents | |
| WO2002096363A3 (en) | Method for treating fibrotic diseases or other indications | |
| BR0107667A (pt) | Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo | |
| WO1999063976A3 (en) | Liver-selective glucocorticoid antagonist for treating diabetes | |
| AU2000276362A1 (en) | Composition for the treatment of diabetes | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| MY134167A (en) | Biphenylcarboxamides useful as lipid lowering agents | |
| BRPI0409359A (pt) | análogos quiméricos de somatostatina-dopamina | |
| ZA200307475B (en) | Carbamate compounds for use in the treatment of pain. | |
| GB9907571D0 (en) | Compounds | |
| SE0004101D0 (sv) | New use | |
| ZA200501288B (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma. | |
| AU4937699A (en) | Use of succinic acid or salts thereof for the treatment of diabetes mellitus andwound healing | |
| NZ504124A (en) | Phenyl-alkyl-imidazoles and use in treating inflammatory disease | |
| HK1044717A1 (zh) | Il-8受体拮抗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A,4A, 5A,6A E 7A ANUIDADES |
|
| B08J | Incorrect entry in the gazette republished [chapter 8.10 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2051 DE 27/04/2010. TEXTO CORRETO: REFERENTE A 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.10 DA RPI 2068 DE 24/08/2010. |